Weekly Cardiology Research Analysis
This week’s cardiology literature emphasized practical therapeutic advances and mechanistic insights with immediate translational potential: (1) two randomized trials/analyses support new peri-procedural and early-in-hospital therapeutic strategies (oral nicorandil to prevent CA‑AKI in high‑risk PCI; early SGLT2 inhibitor initiation in acute HF) and (2) first-in-class oral inotrope AC01 showed a favorable safety profile in HFrEF, enabling phase‑2 planning. Mechanistic and diagnostic innovation i
Summary
This week’s cardiology literature emphasized practical therapeutic advances and mechanistic insights with immediate translational potential: (1) two randomized trials/analyses support new peri-procedural and early-in-hospital therapeutic strategies (oral nicorandil to prevent CA‑AKI in high‑risk PCI; early SGLT2 inhibitor initiation in acute HF) and (2) first-in-class oral inotrope AC01 showed a favorable safety profile in HFrEF, enabling phase‑2 planning. Mechanistic and diagnostic innovation included demonstration of CO2 as a coordinated vasodilator with a novel NIRS-CO2 microvascular readout, offering a new noninvasive assessment of microvascular disease.
Selected Articles
1. Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study.
In a multicenter randomized, double‑blind, placebo‑controlled phase 1b/2a trial (n=58), AC01—an oral calcium‑sensitizing ghrelin receptor agonist—was safe and well tolerated over 7–28 days with no tachycardia, pro‑arrhythmic signals, or biomarker evidence of myocardial injury, supporting dose selection and progression to efficacy trials.
Impact: First randomized clinical evaluation of an oral calcium‑sensitizing/ghrelin‑agonist in HFrEF addresses the unmet need for safer outpatient inotropes and de‑risks further efficacy testing.
Clinical Implications: If phase‑2/3 efficacy is demonstrated, AC01 could become a safer oral inotropic option to support contractility in ambulatory HFrEF without the arrhythmic liabilities of traditional inotropes.
Key Findings
- AC01 was safe and well tolerated over 7–28 days with no AC01‑related serious adverse events.
- No tachycardia, new-onset tachyarrhythmias, or ECG conduction abnormalities were observed; no adverse signals on high‑sensitivity troponin or NT‑proBNP.
2. Nicorandil to Prevent Contrast-Associated Kidney Injury in High-Risk PCI.
A multicenter randomized controlled trial (n=585) randomized patients with renal dysfunction undergoing PCI to high‑dose nicorandil (10 mg TID), conventional dose (5 mg TID), or hydration alone; CA‑AKI incidence fell from 19.8% (control) to 10.9% (conventional) and 8.7% (high‑dose), indicating a dose‑response renoprotective effect.
Impact: Demonstrates a low‑cost, readily available, dose‑dependent intervention to reduce a common and morbid PCI complication, with immediate implementability in cath lab protocols.
Clinical Implications: Consider peri‑procedural oral nicorandil (10 mg TID) as an adjunct to hydration in PCI patients with renal dysfunction to lower CA‑AKI risk; adopt into local protocols while awaiting longer‑term outcome data.
Key Findings
- Randomized 585 high‑risk PCI patients across multicenters with dose stratification.
- CA‑AKI incidence reduced from 19.8% (control) to 10.9% (5 mg TID) and 8.7% (10 mg TID), showing dose‑response benefit.
3. Carbon dioxide is a triple vasodilator.
Mechanistic experiments in mice and human vascular studies show CO2 induces vasodilation via three coordinated pathways—endothelial NO/sGC, EDHF (SKCa/IKCa), and myogenic K+ channels—and introduces NIRS‑CO2 with a time‑to‑intersection (TTI) metric that correlates with PAD/CAD and captures disease‑associated microvascular delay.
Impact: Provides a unifying mechanistic framework for CO2‑mediated vasodilation and delivers a novel, feasible noninvasive microvascular biomarker (NIRS‑CO2) with translational diagnostic potential.
Clinical Implications: NIRS‑CO2 could become a bedside tool to assess integrated endothelial and myogenic microvascular function and track disease or response to therapy; CO2‑linked pathways (NO‑sGC, K+ channels, carbonic anhydrases) nominate pharmacologic targets.
Key Findings
- CO2 elicits vasodilation via endothelial NO/sGC, EDHF (SKCa/IKCa), and myogenic K+ channels (triple mechanism).
- NIRS‑CO2 derived TTI metric correlates with PAD/CAD status and detects delayed microvascular reactivity in disease.